- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
18 F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease ; volume:9 ; number:9 ; year:2017 ; pages:1212-1223 ; extent:12
EMBO molecular medicine / European Molecular Biology Organization ; 9, Heft 9 (2017), 1212-1223 (gesamt 12)
- Urheber
-
Mattsson-Carlgren, Niklas
Schöll, Michael
Strandberg, Olof
Smith, Ruben
Palmqvist, Sebastian
Insel, Philip S.
Hägerström, Douglas
Ohlsson, Tomas
Zetterberg, Henrik
Jögi, Jonas
Blennow, Kaj
Hansson, Oskar
- DOI
-
10.15252/emmm.201707809
- URN
-
urn:nbn:de:101:1-2022100308420731545834
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mattsson-Carlgren, Niklas
- Schöll, Michael
- Strandberg, Olof
- Smith, Ruben
- Palmqvist, Sebastian
- Insel, Philip S.
- Hägerström, Douglas
- Ohlsson, Tomas
- Zetterberg, Henrik
- Jögi, Jonas
- Blennow, Kaj
- Hansson, Oskar
Ähnliche Objekte (12)
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein